Cargando…

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

BACKGROUND: Pneumocystis pneumonia (PCP) is an opportunistic fungal infection that affects immunocompromised patients. Ibrexafungerp (IBX) is an oral and intravenous antifungal from a novel class of glucan synthase inhibitors, triterpenoids, and has shown activity against Candida, Aspergillus, and P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borroto-Esoda, Katyna, Azie, Nkechi, Ashbaugh, Alan, Cushion, Melanie, Angulo, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776520/ http://dx.doi.org/10.1093/ofid/ofaa439.1435

Ejemplares similares

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models
por: Cushion, Melanie T., et al.
Publicado: (2021)

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
por: Sobel, R, et al.
Publicado: (2021)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017)

871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
por: Barat, Stephen, et al.
Publicado: (2017)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017)

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
por: Ghannoum, Mahmoud, et al.
Publicado: (2020)

Anidulafungin Treatment Blocks the Sexual Cycle of Pneumocystis murina and Prevents Growth and Survival without Rescue by an Alternative Mode of Replication
por: Cushion, Melanie T., et al.
Publicado: (2022)

1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)
por: Huang, David, et al.
Publicado: (2021)

1071. Efficacy of Anti-Staphylococcal Lysin, LSVT-1701, in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Huang, David, et al.
Publicado: (2021)

The Effects of Sex and Strain on Pneumocystis murina Fungal Burdens in Mice
por: Macioce-Tisdale, Nikeya L., et al.
Publicado: (2022)

Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection
por: Cushion, Melanie T., et al.
Publicado: (2010)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice
por: Liu, Guan-Sheng, et al.
Publicado: (2018)

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
por: Scorneaux, Bernard, et al.
Publicado: (2017)

The Promise of Lung Organoids for Growth and Investigation of Pneumocystis Species
por: Tisdale-Macioce, Nikeya, et al.
Publicado: (2021)

Correction to: A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice
por: Liu, Guan-Sheng, et al.
Publicado: (2019)

Noninvasive Method for Monitoring Pneumocystis carinii Pneumonia
por: Linke, Michael J., et al.
Publicado: (2003)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Is sex necessary for the proliferation and transmission of Pneumocystis?
por: Hauser, Philippe M., et al.
Publicado: (2018)

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
por: Quindós, Guillermo, et al.
Publicado: (2022)

P1251: BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION
por: Ceccato, J., et al.
Publicado: (2022)

Gene Expression of Pneumocystis murina after Treatment with Anidulafungin Results in Strong Signals for Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating a Requirement for Ascus Formation for Proliferation
por: Cushion, Melanie T., et al.
Publicado: (2018)

Lymphocyte apoptosis in murine Pneumocystis pneumonia
por: Shi, Xin, et al.
Publicado: (2009)

EVALUATING PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP) PROPHYLAXIS IN PATIENTS WITH GLIOMA RECEIVING CONCURRENT TEMOZOLOMIDE AND RADIATION – A PATIENT AND PHYSICIAN SURVEY
por: Beltran-Bless1, Ana-Alicia, et al.
Publicado: (2023)

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
por: Wring, Stephen A., et al.
Publicado: (2017)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia
por: Heffelfinger, James D., et al.
Publicado: (2009)

Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis
por: Dunbar, Albert, et al.
Publicado: (2020)

Treatment and Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients
por: Smith, Don, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rhtpen1f7j0cjofnf48baas3s0